Nathalie Fuentes shared her experience of landing a unicorn position in a pharmaceutical company after a postdoctoral ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Astrazeneca has recently announced 3.5 billion dollars of capital investment in the United States focused on expanding the ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Eric Le Berrigaud has given his Buy rating due to a combination of factors that reflect AstraZeneca’s strong performance and future potential. The company demonstrated robust growth in the third ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...